1. Home
  2. VRTX vs HON Comparison

VRTX vs HON Comparison

Compare VRTX & HON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRTX
  • HON
  • Stock Information
  • Founded
  • VRTX 1989
  • HON 1885
  • Country
  • VRTX United States
  • HON United States
  • Employees
  • VRTX N/A
  • HON N/A
  • Industry
  • VRTX EDP Services
  • HON Aerospace
  • Sector
  • VRTX Technology
  • HON Industrials
  • Exchange
  • VRTX Nasdaq
  • HON Nasdaq
  • Market Cap
  • VRTX 115.6B
  • HON 128.8B
  • IPO Year
  • VRTX 1991
  • HON N/A
  • Fundamental
  • Price
  • VRTX $446.75
  • HON $225.20
  • Analyst Decision
  • VRTX Buy
  • HON Buy
  • Analyst Count
  • VRTX 26
  • HON 13
  • Target Price
  • VRTX $512.54
  • HON $240.67
  • AVG Volume (30 Days)
  • VRTX 2.1M
  • HON 4.2M
  • Earning Date
  • VRTX 05-05-2025
  • HON 07-24-2025
  • Dividend Yield
  • VRTX N/A
  • HON 2.04%
  • EPS Growth
  • VRTX N/A
  • HON 0.81
  • EPS
  • VRTX N/A
  • HON 8.70
  • Revenue
  • VRTX $11,099,700,000.00
  • HON $39,215,000,000.00
  • Revenue This Year
  • VRTX $10.36
  • HON $5.51
  • Revenue Next Year
  • VRTX $10.61
  • HON $4.14
  • P/E Ratio
  • VRTX N/A
  • HON $25.52
  • Revenue Growth
  • VRTX 8.98
  • HON 6.26
  • 52 Week Low
  • VRTX $377.85
  • HON $179.36
  • 52 Week High
  • VRTX $519.88
  • HON $242.77
  • Technical
  • Relative Strength Index (RSI)
  • VRTX 44.94
  • HON 62.44
  • Support Level
  • VRTX $427.43
  • HON $220.82
  • Resistance Level
  • VRTX $448.00
  • HON $225.03
  • Average True Range (ATR)
  • VRTX 11.02
  • HON 3.00
  • MACD
  • VRTX 0.83
  • HON 0.33
  • Stochastic Oscillator
  • VRTX 88.27
  • HON 86.97

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

About HON Honeywell International Inc.

Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.

Share on Social Networks: